MedTrace Logo

Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma

NCT00980707 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-01-19

No results posted yet for this study

Summary

The purpose of this study is to determine the role of versican and hyaluronan measurements in induced sputum as biomarkers of asthma. Enroll 10 subjects with mild persistent asthma who are not receiving treatment with a controller therapy.

Conditions

  • Allergic Asthma

Interventions

DRUG

Inhaled corticosteroid (fluticasone)

inhaled fluticasone 220 ug/bid

Sponsors & Collaborators

  • Benaroya Research Institute

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Associated Scientists to Help Minimize Allergies

    lead OTHER

Principal Investigators

  • Leonard C Altman, MD · Associated Scientists to Help Minimize Allergies

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-06-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00980707 on ClinicalTrials.gov